Radiotheranostics: a roadmap for future development

Ken Herrmann, Markus Schwaiger, Jason S. Lewis, Stephen B. Solomon, Barbara J. McNeil, Michael Baumann, Sanjiv S. Gambhir, Hedvig Hricak, Ralph Weissleder

Research output: Contribution to journalReview articlepeer-review

142 Scopus citations

Abstract

Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. Although some formulations are already approved for human use, more radiopharmaceuticals will enter clinical practice in the next 5 years, potentially introducing new therapeutic choices for patients. Despite these advances, several challenges remain, including logistics, supply chain, regulatory issues, and education and training. By highlighting active developments in the field, this Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development. Multidisciplinary approaches in clinical trial design and therapeutic administration will become essential to the continued progress of this evolving therapeutic approach.

Original languageEnglish
Pages (from-to)e146-e156
JournalLancet Oncology
Volume21
Issue number3
DOIs
StatePublished - Mar 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Radiotheranostics: a roadmap for future development'. Together they form a unique fingerprint.

Cite this